Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

Inclusion Criteria:

* Voluntarily provide written IRB-approved consent
* Age ≥ 18 years
* Histologically proven CTCL
* Stage IIB-IV CTCL with ≥2 cutaneous tumors assessable for response
* At least one cutaneous tumor amenable to radiation therapy. Must have at least 1 tumor assessable for response that will not undergo radiation.
* Adequate organ function
* Prior treatment is allowed if at least 4 weeks have elapsed since last chemotherapy and/or radiation and the subject has recovered from all treatment related toxicity

Exclusion Criteria:

* Prior allogeneic stem cell transplant.
* Prior treatment with a PD-1/PD-L1 inhibitor
* Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment.
* Current or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab.
* Known human immunodeficiency virus (HIV), hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection.
* History of hypersensitivity to durvalumab or any excipient
* Receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab.
* Female subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control
* Male subjects who are not employing an effective method of birth control
* Uncontrolled current medical illness, including, but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris,unstable cardiac arrhythmia and/or psychiatric illness or other condition that in the opinion of the investigator would limit compliance with study requirements.